Discover how advanced Battery Management Systems (BMS) are enhancing electric vehicle efficiency and reliability by embedding ...

MM+M’s Steve Madden is at the JPM Healthcare Conference this week, and he’ll be providing running commentary from the event.

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...

Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

The next wave of AI-enabled operations is reshaping how data centres are run, promising sharper efficiency, tighter security ...

The ‘JP Morgan Healthcare Conference’ opened in San Francisco, U.S., on the 12th (local time). The biggest topic at this year ...

AlphaESS has inaugurated its Nigerian subsidiary in Lagos as energy stakeholders discuss financing, localisation and the ...

North America held a dominan Market position, capturing more than a 33.6% share, holding USD 1.4 Billion revenue.

The New York-based company, previously known as VantAI and incubated at Roivant before a spinoff, is working in a ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...